<DOC>
	<DOCNO>NCT00363545</DOCNO>
	<brief_summary>This trial conduct evaluate immunogenicity , reactogenicity safety liquid formulation GSK Biologicals ' HRV vaccine compare lyophilized formulation GSK Biologicals ' HRV vaccine</brief_summary>
	<brief_title>To Assess Immunogenicity , Reactogenicity &amp; Safety 2 Formulations GSK 's HRV Vaccine 2-dose Vaccination ( Infants )</brief_title>
	<detailed_description />
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female infant , include , 6 12 week age bear gestation period 36 42 week . Written inform consent obtain parent guardian subject . se investigational nonregistered product ( drug vaccine ) HRV vaccine within 30 day precede first dose HRV vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Planned administration/ administration vaccine foreseen study protocol except DTPw , HBV/Hib OPV vaccine within 14 day dose HRV vaccine end 14 day . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . History allergic disease reaction likely exacerbate component vaccine . Household contact immunosuppressed individual pregnant woman . Previous confirm occurrence RV GE .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Prophylaxis gastroenteritis cause Rotavirus</keyword>
</DOC>